<div id="readability-page-1"><p><span>Elanco Animal Health (NYSE:ELAN - Get Free Report)</span> had its price objective boosted by stock analysts at Morgan Stanley  from $18.00 to $22.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an &#34;equal weight&#34; rating on the stock. Morgan Stanley's target price points to a potential downside of 0.97% from the stock's previous close.</p><div><p><span></span><span>Get <strong>Elanco Animal Health</strong> alerts:</span></p></div><ul><li>Bullish or Bearish? Vetting Animal Health Care Stocks</li></ul><p>Other research analysts have also issued research reports about the company. JPMorgan Chase &amp; Co. raised Elanco Animal Health from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and upped their price target for the company from $18.00 to $24.00 in a research report on Tuesday, October 7th. UBS Group lifted their price target on shares of Elanco Animal Health from $25.00 to $27.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, November 6th. Stifel Nicolaus raised their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, September 24th. Barclays began coverage on shares of Elanco Animal Health in a research report on Tuesday, December 9th. They set an &#34;overweight&#34; rating and a $30.00 price target on the stock. Finally, KeyCorp  reissued an &#34;overweight&#34; rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned  a Buy rating, three have assigned  a Hold rating and one  has issued  a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $23.78.</p><p><b>Get Our Latest Analysis on Elanco Animal Health</b></p><h2>Elanco Animal Health Trading Up 0.6%</h2><ul><li>Zoetis Declares New Dividend, Hinting At Undervaluation</li></ul><p>Shares of ELAN stock traded up $0.14 on Thursday, hitting $22.22. 1,352,910 shares of the company's stock traded hands, compared to its average volume of 5,835,690. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The stock has a market capitalization of $11.04 billion, a price-to-earnings ratio of 370.48, a P/E/G ratio of 3.44 and a beta of 1.86. The company's fifty day simple moving average is $21.82 and its 200 day simple moving average is $18.25. Elanco Animal Health has a one year low of $8.02 and a one year high of $23.70. </p><p>Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.13 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The company's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS.  Equities analysts forecast that  Elanco Animal Health will post 0.91 EPS for the current year. </p><h2>Insider Buying and Selling at Elanco Animal Health</h2><ul><li>2 Contrarian Stock Picks With Major Upside</li></ul><p>In related news, insider Rajeev A. Modi acquired 4,500 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average price of $21.33 per share, with a total value of $95,985.00. Following the transaction, the insider directly owned 123,082 shares in the company, valued at approximately $2,625,339.06. This represents a 3.79% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Jeffrey N. Simmons bought 22,000 shares of the company's stock in a transaction on Thursday, December 11th. The stock was bought at an average cost of $21.75 per share, for a total transaction of $478,500.00. Following the completion of the acquisition, the chief executive officer directly owned 167,000 shares of the company's stock, valued at approximately $3,632,250. This represents a 15.17% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 43,450 shares of company stock worth $937,883 in the last ninety days. 0.89% of the stock is owned by company insiders. </p><h2>Hedge Funds Weigh In On Elanco Animal Health</h2><p>Several large investors have recently modified their holdings of ELAN. SJS Investment Consulting Inc. boosted its stake in  Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company's stock worth $28,000 after purchasing an additional 1,333 shares in the last quarter.  Huntington National Bank raised its holdings in  Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company's stock worth $38,000 after buying an additional 1,087 shares during the last quarter.  Whittier Trust Co. of Nevada Inc. lifted its stake in shares of  Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company's stock worth $42,000 after buying an additional 900 shares in the last quarter.  Farther Finance Advisors LLC grew its holdings in shares of  Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company's stock valued at $43,000 after buying an additional 951 shares during the last quarter.  Finally, First Horizon Advisors Inc. increased its position in shares of  Elanco Animal Health by 184.3% during the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company's stock valued at $53,000 after acquiring an additional 2,414 shares in the last quarter. Hedge funds and other institutional investors own  97.48% of the company's stock. </p><h2>About Elanco Animal Health</h2> (Get Free Report)<p>Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.</p><h2>Read More</h2><ul><li>Five stocks we like better than Elanco Animal Health</li><li>Stock Dividend Cuts Happen Are You Ready?</li><li>Dollar General's Turnaround Could Send the Stock Higher in 2026</li><li>The Significance of Brokerage Rankings in Stock Selection</li><li>Don’t Bet Against AppLovin: The Case Against the Shorts</li><li>Canadian Penny Stocks: Can They Make You Rich? </li><li>Micron’s Q1 Results Say “AI Bubble Is Far From Bursting”</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMQU4"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Elanco Animal Health Right Now?</h2><p>Before you consider Elanco Animal Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.</p><p>While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ELAN

<p>Morgan Stanley raised Elanco Animal Health's price target from $18.00 to $22.00, maintaining an "equal weight" rating. Other analysts, including JPMorgan and UBS, have also increased their price targets, with ratings ranging from "buy" to "overweight." The stock has a consensus rating of "Moderate Buy" and a consensus price target of $23.78. Insider buying activity has been reported, with significant share acquisitions by company executives.</p>

Elanco Animal Health (NYSE:ELAN) Price Target Raised to $22.00